Aranda, E <br/><br/>
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  09 2018 
 - 263-272 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2018.06.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cetuximab--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Exanthema--chemically induced<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Leucovorin--administration & dosage<br/>Maintenance Chemotherapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neutropenia--chemically induced<br/>Organoplatinum Compounds--administration & dosage<br/>Proto-Oncogene Proteins p21(ras)--genetics